EX-23.1 4 a2240526zex-23_1.htm EX-23.1

Exhibit 23.1




We hereby consent to the use in this Preliminary Prospectus constituting a part of this Amendment No. 5 to Registration Statement on Form S-1 of Annovis Bio, Inc. (File No. 333-232529) of our report dated May 15, 2019, except for the effects on the financial statements of the restatement described in Note 12, as to which the date is July 2, 2019, and the reverse stock split described in Note 2(j), as to which the date is August 8, 2019 relating to the balance sheets of Annovis  Bio, Inc. as of December 31, 2018 and 2017, and the related statements of operations, changes of redeemable convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the two years in the period then ended.


We also consent to the reference to us under the heading “Experts” in such Registration Statement.


/s/ WithumSmith+Brown, PC




East Brunswick, New Jersey


January 21, 2020